Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)

This study is testing whether giving chemo-immunotherapy (chemotherapy plus an immune-boosting drug) before surgery — followed by more treatment after surgery — can improve outcomes for people with stage III non-small cell lung cancer (NSCLC) whose tumors express a protein called PD-L1. **You may be eligible if...** - You are 18 or older - You have stage III NSCLC confirmed by tissue biopsy - Your tumor tests positive for PD-L1 (at least 1% of cells) - Your tumor does not have EGFR, ALK, ROS1, or RET gene changes (which would make other targeted drugs more appropriate) - You are considered fit enough to receive platinum-based chemotherapy and potentially surgery - You have never smoked, or you are a current or former smoker (note: never-smokers are excluded — see below) **You may NOT be eligible if...** - Your cancer has spread to other parts of the body (stage IV) - You have previously received any cancer treatment for this lung cancer - You have previously received immune checkpoint therapy (anti-PD-1, anti-PD-L1, or anti-CTLA-4) - You have active autoimmune disease - You have never smoked (never-smokers are excluded from this trial) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.